PP_1170x120_10-25-21

Novartis’ Femara

Aurobindo receives FDA approval for letrozole tablets

Aurobindo receives FDA approval for letrozole tablets

EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for letrozole tablets USP, 2.5 mg. Aurobindo’s letrozole tablets are an AB-rated generic equivalent to the reference listed drug, Novartis’ Femara. Letrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone